XOMA Royalty Corp (XOMA): M&A transaction — XOMA completes acquisition of LAVA Therapeutics for $1.04/share plus CVRs

XOMA Royalty Corp

Subsequent Offering Period expired Nov 20, 2025; Post-Offer Reorganization effective same day.
All LAVA shareholders who did not tender receive cash ($1.04/share) and one CVR for future payments.
XOMA will file LAVA's financial statements and pro forma info in an amendment to this 8-K.

item 2.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

XOMA Royalty Corp completed an acquisition involving LAVA Therapeutics N.V. (closed 2025-11-20).

Action: acquisition
Counterparty: LAVA Therapeutics N.V.
Closing: 2025-11-20

Exact text from the filing

XOMA and LAVA effectuated the Post-Offer Reorganization, which became effective on November 20, 2025.

View on SEC.gov

5 m&a transactions filed in the last 30 days. Browse all m&a transactions →

XOMA Royalty Corp filing history →

Source: SEC EDGAR

accession 0001193125-25-290638

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.